Clinical Trial Update: Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study comparing Lunsekimig to placebo in adults with moderate-to-severe asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Lunsekimig (Lunsekimig)

Snippet

Sponsor: Sanofi | Conditions: Asthma | Phase 2 | Status: COMPLETED